Taysha Gene Therapies (TSHA) Income from Continuing Operations (2020 - 2026)
Taysha Gene Therapies (TSHA) reported Income from Continuing Operations of 98114000.0 for Q1 2026, down 243.13% on a YoY basis from 68549863.56 in Q1 2025, and down 285.64% sequentially from 25442000.0 in Q4 2025.
Taysha Gene Therapies (TSHA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Taysha Gene Therapies (TSHA) has 7 years of Income from Continuing Operations data on file, last reported at 98114000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 243.13% year-over-year to 98114000.0; the trailing twelve-month figure through Mar 2026 stood at 236710000.0 (down 88.95% YoY), and the FY2025 full-year result was 182951000.0, up 7.9% from the prior year.
- Income from Continuing Operations fell to 98114000.0 in Q1 2026, from 25442000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 14354000.0 in Q4 2024 to a low of 98114000.0 in Q1 2026.
- A 5-year average of 40680058.82 and a median of 34116000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations soared 72.12% in 2023 and plunged 243.13% in 2026, its largest moves.
- Tracing TSHA's Income from Continuing Operations over 5 years: stood at 56006000.0 in 2022, then soared by 72.12% to 15612000.0 in 2023, then rose by 8.06% to 14354000.0 in 2024, then sank by 77.25% to 25442000.0 in 2025, then slumped by 285.64% to 98114000.0 in 2026.
- Business Quant data shows TSHA's Income from Continuing Operations at 98114000.0 in Q1 2026, 25442000.0 in Q4 2025, and 61988000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Taysha Gene Therapies | 2.14 Bn | 2.14 Bn | - | -98.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -98.11 Mn |
| Dec 31, 2025 | -25.44 Mn |
| Sep 30, 2025 | -61.99 Mn |
| Jun 30, 2025 | -51.17 Mn |
| Mar 31, 2025 | -28.59 Mn |
| Dec 31, 2024 | -14.35 Mn |
| Sep 30, 2024 | -52.88 Mn |
| Jun 30, 2024 | -29.46 Mn |
| Mar 31, 2024 | -36.93 Mn |
| Dec 31, 2023 | -15.61 Mn |
| Sep 30, 2023 | -26.04 Mn |
| Jun 30, 2023 | -55.53 Mn |
| Mar 31, 2023 | -28.18 Mn |
| Dec 31, 2022 | -56.01 Mn |
| Sep 30, 2022 | -26.54 Mn |
| Jun 30, 2022 | -34.12 Mn |
| Mar 31, 2022 | -50.63 Mn |
| Dec 31, 2021 | -75.24 Mn |
| Sep 30, 2021 | -51.22 Mn |
| Jun 30, 2021 | -45.27 Mn |